Cytostatic and Cytotoxic Effects of Topotecan Decoded by a Novel Mathematical Simulation Approach

Monica Lupi, Giada Matera, Davide Branduardi, Maurizio D'Incalci, Paolo Ubezio

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Topotecan (TPT) is a topoisomerase I inhibitor, and like the other drugs of this family, it is believed to act in a specific way on cells in S phase at the time of treatment. Exploiting a new method, coupling a particular experimental plan with computer simulation, a complete quantitative study of the time dependence and dose dependence of the activity of cell cycle controls has become feasible, and the overall scenario of events after treatment can be reconstructed in detail. We were able to demonstrate that the response of an ovarian cancer cell line to 1 h of treatment with TPT is not limited to inhibition of DNA synthesis, leading to cell death, but involves G1 and G2-M checkpoints. G1 and G2-M block, recycling, and death follow specific dose-dependent kinetics, lasting no less than 3 days after treatment. We also found that cells treated outside S phase contribute significantly to the overall activity. The utility of this analysis was demonstrated by reproducing more complex treatment schemes in which low TPT concentrations were applied for 1 h three times at 24-h intervals. In this case, the simulation clarified the origin of the auto-potentiation observed with repeated 0.2 μm treatments, in which the cytotoxicity, particularly against S-phase cells, was higher than the cytotoxicity in cells treated with 10 μm only once. We believe that this approach will help us to understand the complexity and heterogeneity of the response of a cell population to a drug challenge and could help us to establish the rationale for drug scheduling or drug combinations.

Original languageEnglish
Pages (from-to)2825-2832
Number of pages8
JournalCancer Research
Volume64
Issue number8
DOIs
Publication statusPublished - Apr 15 2004

Fingerprint

Topotecan
Cytostatic Agents
S Phase
Pharmaceutical Preparations
Topoisomerase I Inhibitors
Activity Cycles
Recycling
Drug Combinations
Cell Cycle Checkpoints
Computer Simulation
Ovarian Neoplasms
Cell Death
Cell Line
DNA
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cytostatic and Cytotoxic Effects of Topotecan Decoded by a Novel Mathematical Simulation Approach. / Lupi, Monica; Matera, Giada; Branduardi, Davide; D'Incalci, Maurizio; Ubezio, Paolo.

In: Cancer Research, Vol. 64, No. 8, 15.04.2004, p. 2825-2832.

Research output: Contribution to journalArticle

@article{cd4d3cb0e56b42c185d5bcf549fc0f77,
title = "Cytostatic and Cytotoxic Effects of Topotecan Decoded by a Novel Mathematical Simulation Approach",
abstract = "Topotecan (TPT) is a topoisomerase I inhibitor, and like the other drugs of this family, it is believed to act in a specific way on cells in S phase at the time of treatment. Exploiting a new method, coupling a particular experimental plan with computer simulation, a complete quantitative study of the time dependence and dose dependence of the activity of cell cycle controls has become feasible, and the overall scenario of events after treatment can be reconstructed in detail. We were able to demonstrate that the response of an ovarian cancer cell line to 1 h of treatment with TPT is not limited to inhibition of DNA synthesis, leading to cell death, but involves G1 and G2-M checkpoints. G1 and G2-M block, recycling, and death follow specific dose-dependent kinetics, lasting no less than 3 days after treatment. We also found that cells treated outside S phase contribute significantly to the overall activity. The utility of this analysis was demonstrated by reproducing more complex treatment schemes in which low TPT concentrations were applied for 1 h three times at 24-h intervals. In this case, the simulation clarified the origin of the auto-potentiation observed with repeated 0.2 μm treatments, in which the cytotoxicity, particularly against S-phase cells, was higher than the cytotoxicity in cells treated with 10 μm only once. We believe that this approach will help us to understand the complexity and heterogeneity of the response of a cell population to a drug challenge and could help us to establish the rationale for drug scheduling or drug combinations.",
author = "Monica Lupi and Giada Matera and Davide Branduardi and Maurizio D'Incalci and Paolo Ubezio",
year = "2004",
month = "4",
day = "15",
doi = "10.1158/0008-5472.CAN-03-3810",
language = "English",
volume = "64",
pages = "2825--2832",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Cytostatic and Cytotoxic Effects of Topotecan Decoded by a Novel Mathematical Simulation Approach

AU - Lupi, Monica

AU - Matera, Giada

AU - Branduardi, Davide

AU - D'Incalci, Maurizio

AU - Ubezio, Paolo

PY - 2004/4/15

Y1 - 2004/4/15

N2 - Topotecan (TPT) is a topoisomerase I inhibitor, and like the other drugs of this family, it is believed to act in a specific way on cells in S phase at the time of treatment. Exploiting a new method, coupling a particular experimental plan with computer simulation, a complete quantitative study of the time dependence and dose dependence of the activity of cell cycle controls has become feasible, and the overall scenario of events after treatment can be reconstructed in detail. We were able to demonstrate that the response of an ovarian cancer cell line to 1 h of treatment with TPT is not limited to inhibition of DNA synthesis, leading to cell death, but involves G1 and G2-M checkpoints. G1 and G2-M block, recycling, and death follow specific dose-dependent kinetics, lasting no less than 3 days after treatment. We also found that cells treated outside S phase contribute significantly to the overall activity. The utility of this analysis was demonstrated by reproducing more complex treatment schemes in which low TPT concentrations were applied for 1 h three times at 24-h intervals. In this case, the simulation clarified the origin of the auto-potentiation observed with repeated 0.2 μm treatments, in which the cytotoxicity, particularly against S-phase cells, was higher than the cytotoxicity in cells treated with 10 μm only once. We believe that this approach will help us to understand the complexity and heterogeneity of the response of a cell population to a drug challenge and could help us to establish the rationale for drug scheduling or drug combinations.

AB - Topotecan (TPT) is a topoisomerase I inhibitor, and like the other drugs of this family, it is believed to act in a specific way on cells in S phase at the time of treatment. Exploiting a new method, coupling a particular experimental plan with computer simulation, a complete quantitative study of the time dependence and dose dependence of the activity of cell cycle controls has become feasible, and the overall scenario of events after treatment can be reconstructed in detail. We were able to demonstrate that the response of an ovarian cancer cell line to 1 h of treatment with TPT is not limited to inhibition of DNA synthesis, leading to cell death, but involves G1 and G2-M checkpoints. G1 and G2-M block, recycling, and death follow specific dose-dependent kinetics, lasting no less than 3 days after treatment. We also found that cells treated outside S phase contribute significantly to the overall activity. The utility of this analysis was demonstrated by reproducing more complex treatment schemes in which low TPT concentrations were applied for 1 h three times at 24-h intervals. In this case, the simulation clarified the origin of the auto-potentiation observed with repeated 0.2 μm treatments, in which the cytotoxicity, particularly against S-phase cells, was higher than the cytotoxicity in cells treated with 10 μm only once. We believe that this approach will help us to understand the complexity and heterogeneity of the response of a cell population to a drug challenge and could help us to establish the rationale for drug scheduling or drug combinations.

UR - http://www.scopus.com/inward/record.url?scp=9644288331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9644288331&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-03-3810

DO - 10.1158/0008-5472.CAN-03-3810

M3 - Article

C2 - 15087399

AN - SCOPUS:9644288331

VL - 64

SP - 2825

EP - 2832

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 8

ER -